Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

953
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
953
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

614
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
614
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

342
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
342
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

527
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
527

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid detection of treatment-emergent resistance to bedaquiline and pretomanid in <i>Mycobacterium tuberculosis</i> using TM4::<i>GeNL</i> reporter mycobacteriophages.

Microbiology spectrum·2026
Same author

Compositional and interpretable representation of histology using AI foundation models and sparse autoencoders.

bioRxiv : the preprint server for biology·2026
Same author

Modeling development of tertiary lymphoid structures in pulmonary tuberculosis by 3D profiling and trajectory analysis.

bioRxiv : the preprint server for biology·2026
Same author

NETosis associates with human TB lung tissue destruction and disease pathogenesis.

EMBO molecular medicine·2026
Same author

Glucose selectively drives a rapid oxidative burst and immunometabolic reprogramming in human neutrophils during <i>Mycobacterium tuberculosis</i> infection.

bioRxiv : the preprint server for biology·2026
Same author

A whole-blood transcriptional signature associated with obstructive post-tuberculosis lung disease.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Remembering the Host in Tuberculosis Drug Development.

Daniel J Frank1, David J Horne2, Noton K Dutta3

  • 1Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

The Journal of Infectious Diseases
|December 28, 2018
PubMed
Summary

New host-directed therapies (HDTs) are crucial for combating drug-resistant tuberculosis (TB). This review highlights recent advances in HDTs, focusing on novel drugs, pathways, and concepts for developing effective treatments.

Keywords:
drug developmenthost-directed therapymacrophagemeningitistuberculosis

More Related Videos

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.4K
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Related Experiment Videos

Last Updated: Jan 31, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.4K
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • Tuberculosis (TB) treatment requires new therapeutics to shorten duration and overcome drug resistance.
  • Emergence of drug-resistant TB necessitates novel treatment strategies.
  • Host-directed therapy (HDT) presents a promising alternative by modulating host immune responses.

Purpose of the Study:

  • To review recent data on drugs, pathways, and concepts relevant to developing HDTs for TB.
  • To discuss challenges and strategies for advancing HDT development.
  • To highlight the importance of novel mechanisms of action against drug-resistant TB.

Main Methods:

  • Literature review of recent scientific data on HDTs for TB.
  • Discussion of concepts presented at the "Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB" workshop.
  • Synthesis of information on drugs, pathways, and therapeutic strategies.

Main Results:

  • HDTs offer novel mechanisms to activate immune defenses and reduce tissue damage.
  • Repurposing existing drugs and exploring new pathways are key strategies.
  • Successful HDT development requires addressing specific challenges in drug discovery and clinical application.

Conclusions:

  • HDTs represent a critical new approach to combatting tuberculosis, especially drug-resistant strains.
  • Further research into specific drugs, host pathways, and strategic development is essential.
  • Collaboration and focused discussion, like that at the Gordon Research Conference, are vital for advancing HDT research.